Form 8-K - Current report:
SEC Accession No. 0001815776-24-000039
Filing Date
2024-05-08
Accepted
2024-05-08 16:05:56
Documents
15
Period of Report
2024-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lenz-20240508.htm   iXBRL 8-K 26543
2 EX-99.1 a991pressrelease.htm EX-99.1 52670
6 image_0a.jpg GRAPHIC 28536
  Complete submission text file 0001815776-24-000039.txt   257512

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lenz-20240508.xsd EX-101.SCH 1889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lenz-20240508_lab.xml EX-101.LAB 23433
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lenz-20240508_pre.xml EX-101.PRE 13570
19 EXTRACTED XBRL INSTANCE DOCUMENT lenz-20240508_htm.xml XML 3126
Mailing Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014
Business Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40532 | Film No.: 24925861
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)